Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.

Division of Infectious Diseases, Department of Medicine, Inflammatory Diseases Institute, and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Gastroenterology (Impact Factor: 13.93). 11/2010; 140(2):667-75. DOI: 10.1053/j.gastro.2010.10.056
Source: PubMed

ABSTRACT Several small molecule inhibitors of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease have advanced successfully to clinical trials. However, the selection of drug-resistant mutants is a significant issue with protease inhibitors (PIs). A variety of amino acid substitutions in the protease domain of NS3 can lead to PI resistance. Many of these significantly impair the replication fitness of HCV RNA replicons. However, it is not known whether these mutations also adversely affect infectious virus assembly and release, processes in which NS3 also participates.
We studied the impact of 25 previously identified PI-resistance mutations on the capacity of genotype 1a H77S RNA to replicate in cell culture and produce infectious virus.
Most PI-resistance mutations resulted in moderate loss of replication competence, although several (V36A/L/M, R109K, and D168E) showed fitness comparable to wild type, whereas others (S138T and A156V) were severely impaired both in RNA replication and infectious virus production. Although reductions in RNA replication capacity correlated with decreased yields of infectious virus for most mutations, a subset of mutants (Q41R, F43S, R155T, A156S, and I170A/T) showed greater impairment in their ability to produce virus than predicted from reductions in RNA replication capacity. Detailed examination of the I170A mutant showed no defect in release of virus from cells and no significant difference in specific infectivity of extracellular virus particles.
Replicon-based assays might underestimate the loss of fitness caused by PI-resistance mutations, because some mutations in the NS3 protease domain specifically impair late steps in the viral life cycle that involve intracellular assembly of infectious virus.

Download full-text


Available from: David Mcgivern, Aug 13, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The development and evaluation of effective therapies and vaccines for the hepatitis C virus (HCV) and the study of its interactions with the mammalian host have been hindered for a long time by the absence of suitable small animal models. Due to the narrow host tropism of HCV, the development of mice that can be robustly engrafted with human hepatocytes was a major breakthrough since they recapitulate the complete HCV life cycle. This model has been useful to investigate many aspects of the HCV life cycle, including antiviral interventions. However, studies of cellular immunity, immunopathogenesis and resulting liver diseases have been hampered by the lack of a small animal model with a functional immune system. In this review, we summarize the evolution of in vivo models for the study of HCV.
    Journal of Hepatology 11/2014; 61(1). DOI:10.1016/j.jhep.2014.07.013 · 10.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) infection is a serious public health problem throughout the world. Great success has been achieved in developing inhibitors targeting the HCV NS3/4A protease over the past decade, but the rapid emergence of drug resistant mutations greatly compromises the efficacy of antiviral drugs or drug candidates. According to the substrate envelope hypothesis (PNAS, 2010, 107, 20986), severe drug resistant mutations would always occur where the inhibitors protrude from the substrate envelope, defined as a consensus volume occupied by the viral substrates in the active site of the NS3/4A protease. However, the substrate envelope hypothesis just qualitatively assesses the impact of mutations to a specific inhibitor, but no quantitative data is obtained. To remedy the weakness, the dynamic binding patterns of HCV NS3/4A protease inhibitors or substrates were investigated by molecular dynamics (MD) simulations and continuum solvation binding affinity predictions in this study. By comparing the quantitative binding profiles between the substrates and inhibitors, derived from the free energy decomposition analysis, we observed most residues involved in drug resistance form stronger interactions with the inhibitors than with the substrates, which is roughly coincident with the substrate envelope hypothesis and supports the general mechanism of drug resistance: the critical resistant mutations impair more to the binding of inhibitors than that of substrates. Furthermore, our predictions illustrate that the natural substrates of NS3/4A form balanced interactions with the strands 135-139 and 154-160 whereas the inhibitors cannot. Therefore, to overcome drug resistance, it may be necessary to restore the interaction balance between the two strands and the drug candidates. To our disappointment, the underlying resistant mechanisms of some mutations could not be well captured by just comparing the binding profiles of the inhibitors and substrates., and more studies should be proceeded to propose a general drug resistance mechanism.
    Antiviral Research 05/2014; 103:60-70. DOI:10.1016/j.antiviral.2014.01.010 · 3.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent advances in molecular biology have led to the development of novel small molecules that target specific viral proteins of the hepatitis C virus (HCV) life cycle. These drugs, collectively termed directly acting antivirals (DAA) against HCV, include a range of non-structural (NS) 3/NS4A protease, NS5B polymerase, and NS5A inhibitors at various stages of clinical development. The rapid replication rate of HCV, along with the low fidelity of its polymerase, gives rise to generations of mutations throughout the viral genome resulting in remarkable sequence variation in the HCV population, known as a quasispecies. The efficacy of DAAs is limited by the presence of those mutations that give rise to amino-acid substitutions within the targeted protein, and that affect the viral sensitivity to these compounds. Thus, due to the high genetic variability of HCV, variants with reduced susceptibility to DAA can occur naturally even before treatment begins, but usually at low levels. Not surprisingly then, these changes are selected in patients either breaking through or not responding to potent DAA treatment. In vitro or in vivo, six major position mutations in the NS3 HCV protease (36, 54, 155, 156, 168, and 170) have now been reported associated with different levels of resistance. The amino acid composition at several of the drug resistance sites can vary between the HCV genotypes/subtypes, resulting in different consensus amino acids leading to a reduction in replicative fitness as well as reduced DAA sensitivity. Different amino acid diversity profiles for HCV genotypes/subtypes suggest differences in the position/type of immune escape and drug resistance mutations. Also, different pathways of resistance profiles based on the chemical scaffold (linear or macrocyclic) of the protease inhibitors have been described. This review first describes how resistance to a protease inhibitor can develop and then provides an overview of the mechanism of how particular mutations confer varying levels of resistance to protease inhibitor, which have been identified and characterized using both genotypic and phenotypic tools. Future potential therapeutic strategies to assist patients who do develop resistance to protease inhibitors are also outlined. The challenge developing new HCV protease inhibitors should take into consideration not only the antiviral potency of the drugs, the occurrence and importance of side effects, the frequency of oral administration, but also the resistance profiles of these agents.
    Journal of Hepatology 07/2011; 55(1):192-206. DOI:10.1016/j.jhep.2011.01.011 · 10.40 Impact Factor